Abstract 546P
Background
Malignant pleural mesothelioma (MPM) is an asbestos-related fatal malignant neoplasm. Although combination therapy of ipilimumab plus nivolumab has proven to bring about a better outcome in patients with MPM, long-term survival remains unsatisfactory. To further improve the prognosis, developing a novel treatment strategy to maximize the antitumor effect of ICI is a pressing issue. We examined whether nintedanib, an antiangiogenic agent, could augment the antitumor effect of anti-PD-1 antibody (Ab).
Methods
We established subcutaneous mice mesothelioma allograft model. Mice were treated either with vehicle, anti-PD-1 Ab, nintedanib or anti-PD-1 Ab plus nintedanib. Tumor size was routinely measured with a caliper. Mice were euthanized before they became moribund, and allografts were collected for histological analyses. Angiogenesis and infiltrating immune cells were assessed by immunohistochemistry (IHC). We further performed ex vivo study using bone marrow-derived macrophages (BMDMs) to elucidate the antitumor mechanism of the combination therapy of anti-PD-1 Ab plus nintedanib.
Results
Nintedanib significantly suppressed the growth of mesothelioma allografts. Combination therapy with anti-PD-1 Ab plus nintedanib reduced tumor burden more dramatically compared with nintedanib monotherapy. IHC analyses revealed that nintedanib not only inhibited angiogenesis but also decreased the infiltration of tumor-associated macrophages (TAMs). Moreover, ex vivo study using BMDMs showed that nintedanib could polarize TAMs from M2 to M1 phenotype. Thus, nintedanib could suppress protumor activity of TAMs both numerically and functionally. On the other hand, nintedanib upregulated the expression of PD-1 and PD-L1 in BMDMs and mesothelioma cells, respectively, and impaired the phagocytic activity of BMDMs against mesothelioma cells. Co-administration of anti-PD-1 Ab may reactivate phagocytic activity of BMDMs by disrupting nintedanib-induced immunosuppressive signal.
Conclusions
Combination therapy of anti-PD-1 Ab plus nintedanib exerts synergistic antitumor activity and can become a novel therapeutic option for patients with MPM.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
T. Minami: Financial Interests, Institutional, Research Grant: Nippon Boehringer Ingelheim. All other authors have declared no conflicts of interest.
Resources from the same session
471TiP - A group sequential, response-adaptive randomized double-blinded clinical trial to evaluate add-on olanzapine plus pregabalin to prevent chemotherapy-induced nausea and vomiting (CINV ) in patients belonging to low socio-economic status
Presenter: Mathan Ramasubbu
Session: Poster Display
Resources:
Abstract
472P - Risk of recurrence and optimal adjuvant treatment in invasive lung adenocarcinomas manifesting as radiological part-solid nodules
Presenter: Yang Wo
Session: Poster Display
Resources:
Abstract
473P - Treatment (tx) patterns in resectable stage IA–IIIA non-small cell lung cancer (NSCLC) in China: Subgroup analysis of a global real-world (rw) study
Presenter: Chih-Chi Yang
Session: Poster Display
Resources:
Abstract
474P - The efficacy of image guided coil localisation for surgical resection of undiagnosed solitary lung nodule
Presenter: Jun Rey Leong
Session: Poster Display
Resources:
Abstract
475P - 5-year overall survival and disease free survival outcome between lobectomy and segmentectomy for early stage lung cancer in a mixed Asian population
Presenter: Jianye Chen
Session: Poster Display
Resources:
Abstract
478P - Peri-operative risks in curative lung resection of early stage primary lung cancer patients above 70 years old in a mixed Asian population
Presenter: Ian Goh
Session: Poster Display
Resources:
Abstract
480P - Aumolertinib as adjuvant therapy for resectable stage I-III EGFR-mutant NSCLC: Also effective in EGFR co-mutation
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
481P - Comparative analysis of three NGS platforms assessing tumor mutational burden and mutational landscape in resectable non-small cell lung cancer
Presenter: Jii Bum Lee
Session: Poster Display
Resources:
Abstract
482P - Prevalence of EGFR mutations (EGFRm) and its subtypes in patients (pts) with resected stage I-III NSCLC: Results from EARLY-EGFR Singapore cohort
Presenter: Puey Ling Chia
Session: Poster Display
Resources:
Abstract
483P - Genetic profiles and evolutionary trajectory of early stage lung adenocarcinoma (AAH, AIS, MIA and IAC) revealed by multiplex sequecing
Presenter: lixuan lin
Session: Poster Display
Resources:
Abstract